# Efficacy and Safety of Mexidol® in Stroke Therapy

Study · id `cardio:ct-nct06437626` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06437626](<https://clinicaltrials.gov/study/NCT06437626>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06437626

Browse, organ or system: Brain  
Browse, condition area: Stroke  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 304 participants.

## Technical summary

Registry record NCT06437626. Randomized; double masking; primary purpose treatment. Start 2019-11-18 (actual); primary completion 2023-08-18 (actual). Results posted on 2025-12-08.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 304 participants (enrolled count; ClinicalTrials.gov record NCT06437626, source copy `cardio:ctgov-nct06437626-2025-12-30`, retrieved 2026-10-26)
- Started: 2019-11-18 (actual) (ClinicalTrials.gov record NCT06437626, source copy `cardio:ctgov-nct06437626-2025-12-30`, retrieved 2026-10-26)
- Primary completion: 2023-08-18 (actual) (ClinicalTrials.gov record NCT06437626, source copy `cardio:ctgov-nct06437626-2025-12-30`, retrieved 2026-10-26)
- Completion: 2023-08-18 (actual) (ClinicalTrials.gov record NCT06437626, source copy `cardio:ctgov-nct06437626-2025-12-30`, retrieved 2026-10-26)
- Results first posted: 2025-12-08 (ClinicalTrials.gov record NCT06437626, source copy `cardio:ctgov-nct06437626-2025-12-30`, retrieved 2026-10-26)
- Countries: Kazakhstan; Russia; Uzbekistan (ClinicalTrials.gov record NCT06437626, source copy `cardio:ctgov-nct06437626-2025-12-30`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06437626-2025-12-30`, retrieved 2026-10-26)

## The registry's words

- Brief title: Efficacy and Safety of Mexidol® in Stroke Therapy
- Acronym: MIR
- Condition: Ischemic Stroke
- Intervention (Drug): Mexidol (Ethylmethylhydroxypyridine Succinate)
- Intervention (Drug): Placebo
- Lead sponsor: Pharmasoft
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Ischemic stroke (`cardio:ischemic-stroke`)
- Registry condition terms include this condition: Stroke (`core:stroke`)
- Registry lists this organization as the lead sponsor: Pharmasoft (`cardio:org-pharmasoft`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: \[Multimodal antioxidant therapy in ischemic stroke: from MIR trial to bedside\] (`cardio:pubmed-41456191`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 1a3b8de608a1aa214f95da6a57918dd3437c0f469d2fcbe93dae53b0b74769ab
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
